NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Thanks for the thoughtful question. It is entirely reasonable to ask whether the inclusion of Flaskworks in the MAA should have triggered a public disclosure under SEC rules. Based on what is publicly known, it likely did not meet that threshold.

Flaskworks was fully acquired by NWBO in 2020, and its intended role in automating dendritic cell manufacturing has been disclosed in prior filings and public commentary. Its integration into the production strategy was already understood as part of NWBO’s long-term platform.

Under SEC regulations, a company is required to disclose developments only if they are considered material. Materiality is defined as information for which there is a substantial likelihood that a reasonable investor would view it as important when making an investment decision. This standard comes from the U.S. Supreme Court decision in TSC Industries v. Northway.

Unless the use of Flaskworks in the MAA introduced a new risk profile, financial shift, or regulatory impact, the company would not be legally required to file a new disclosure. So far, NWBO has not reported any such change.

While Flaskworks may be strategically important, especially to those closely tracking the company’s manufacturing evolution, its inclusion in the MAA appears to have been consistent with prior disclosures. Based on that, it likely did not rise to the level of materiality that would mandate separate public notification.